Zemaira Drug Information
Generic name: ALPHA-1-PROTEINASE INHIBITOR HUMAN
Uses of Zemaira
ZEMAIRA is an alpha 1 -proteinase inhibitor (A 1 -PI) indicated for chronic augmentation and maintenance therapy in adults with A 1 -PI deficiency and clinical evidence of emphysema. ZEMAIRA increases antigenic and functional (anti-neutrophil elastase capacity ) serum levels and lung epithelial lining fluid (ELF) levels of A 1 -PI. Clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with ZEMAIRA are not available.
The effect of augmentation therapy with ZEMAIRA or any A 1 -PI product on pulmonary exacerbations and on the progression of emphysema in A 1 -PI deficiency has not been demonstrated in randomized, controlled clinical studies. ZEMAIRA is not indicated as therapy for lung disease patients in whom severe A 1 -PI deficiency has not been established.
Dosage & Administration of Zemaira
Preparation and Reconstitution Check the expiration date on the vial label and carton. Do not use ZEMAIRA after the expiration date. Reconstitute prior to use according to the instructions provided below.
Reconstitute ZEMAIRA using aseptic technique to maintain product sterility. Total reconstitution time for a 1g vial should be obtained within 5 minutes. Total reconstitution time for a 4g or 5g vial should be obtained within 10 minutes.
Inspect the reconstituted solution prior to administration. The solution should be clear, colorless to slightly yellow, and free from visible particles. Reconstituted ZEMAIRA may be stored at room temperature.
Do not freeze the reconstituted solution. Follow the steps provided below for the preparation and reconstitution of ZEMAIRA: 1. Ensure that the ZEMAIRA vial and Sterile Water for Injection vial are at room temperature. 2.
Remove the plastic flip-top cap from the Sterile Water for Injection vial. 3. Wipe the rubber stopper of the Sterile Water for Injection vial with antiseptic solution and allow it to dry. 4. Open the Mix2Vial ® filter transfer set by peeling off the lid (Fig. 1).
Do not remove the transfer set from the blister package. Fig. 1 5. Place the Sterile Water for Injection vial on an even, clean surface and hold the vial tight.
Take the transfer set together with the blister package and vertically pierce the Sterile Water for Injection vial with the blue tip of the transfer set (Fig. 2). Fig. 2 6. Carefully remove the blister package from the transfer set by holding at the rim, and pulling vertically upwards.
Make sure that you only pull away the blister package and not the transfer set (Fig. 3). Fig. 3 7. Remove the plastic flip-top cap from the ZEMAIRA vial. 8.
Wipe the rubber stopper of the ZEMAIRA vial with antiseptic solution and allow it to dry. 9. Place the ZEMAIRA vial on an even and firm surface. Invert the Sterile Water for Injection vial with the transfer set attached and vertically pierce the ZEMAIRA vial with the clear tip of the transfer set (Fig. 4).
The Sterile Water for Injection will automatically flow into the ZEMAIRA vial. Note: Ensure all water has transferred into the ZEMAIRA vial. Fig. 4 10.
Follow steps below to remove entire transfer set from ZEMAIRA vial: With one hand tightly grasp the ZEMAIRA vial as shown in Fig. 5. With the other hand tightly grasp Sterile Water for Injection vial and blue transfer set. Bend the entire transfer set to the side until it disconnects from the ZEMAIRA vial (Fig. 5).
Discard the Sterile Water for Injection vial with the entire transfer set. Fig. 5 11. Gently swirl the ZEMAIRA vial until the powder is completely dissolved (Fig. 6).
DO NOT SHAKE. Take care not to touch the rubber vial stopper. Fig. 6 If more than 1 vial of ZEMAIRA is needed to achieve the required dose, use aseptic technique to transfer the reconstituted solution from the vials into the administration container (e.g., empty intravenous bag or glass bottle).
Fig. Administration For intravenous use only. Do not mix ZEMAIRA with other medicinal products; administer ZEMAIRA through a separate dedicated infusion line.
Perform a visual inspection of the reconstituted solution. Administer at room temperature within 3 hours after reconstitution. Filter the reconstituted solution during administration.
To ensure proper filtration of ZEMAIRA, use an intravenous administration set with a suitable 5 micron infusion filter (not supplied). Administer ZEMAIRA intravenously at a rate of approximately 0.08 mL/kg/min as determined by the response and comfort of the patient. The recommended dosage of 60 mg/kg body weight will take approximately 15 minutes to infuse.
Monitor closely the infusion rate and the patient's clinical state, including vital signs, throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.
ZEMAIRA is for single dose only. Following administration, discard any unused solution and all administration equipment in an appropriate manner as per local requirements.
Side Effects of Zemaira
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug product cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Post-Licensure Open-label extension of the RAPID trial involving 140 subjects who had completed blinded treatment with ZEMAIRA or placebo for 24 months in the RAPID trial and who entered the extension trial and received open-label ZEMAIRA for up to an additional 24 months (referred to as years 3 and 4 in Table 3). Table 1 summarizes the ARs, expressed as events per subject-year, and the corresponding number of ARs per infusion, expressed as % of all infusions, for each treatment in pre-licensure clinical trials of ZEMAIRA.
Table 1. Overall Adverse Reactions (ARs) and Serious ARs Table 2 summarizes the ARs occurring in 5% or more (>3) subjects, expressed as events per subject-year, and the corresponding number of ARs per infusion, expressed as % of all infusions, for each treatment in clinical trials of ZEMAIRA. Table 2.
Adverse Reactions Occurring in ≥5% of Subjects Diffuse interstitial lung disease was noted on a routine chest x-ray of one subject at Week 24. Causality could not be determined. Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In a retrospective analysis, during the 10-week blinded portion of the 24-week clinical trial, 6 subjects (20%) of the 30 treated with ZEMAIRA had a total of 7 exacerbations of their chronic obstructive pulmonary disease (COPD).
Nine subjects (64%) of the 14 treated with Prolastin had a total of 11 exacerbations of their COPD. Subjects who were randomized to ZEMAIRA in the 2-year RAPID trial who then entered and received open-label ZEMAIRA in the 2 year RAPID extension trial were in the "Early Start" group. Table 3.
Comparison of Exposure-Adjusted Incidence Rates (EAIR) for Serious COPD Exacerbations Occurring in the RAPID study between ZEMAIRA and Placebo subjects and in the RAPID Extension Studies between Early Start and Delayed Start subjects In the 24-week double-blind trial, ZEMAIRA-treated subjects were tested for HAV, HBV, HCV, HIV, and parvovirus B19 (B19V), and no evidence of virus transmission was observed.
Immunogenicity As with all therapeutic proteins, there is potential for immunogenicity. No anti-A 1 PI antibodies have been detected in clinical trials of ZEMAIRA. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ZEMAIRA with the incidence of antibodies to other products may be misleading.
Postmarketing Experience
Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. Table 4 lists the ARs that have been identified during postmarketing use of ZEMAIRA. This list does not include reactions already reported in clinical trials with ZEMAIRA.
Table 4. ARs Reported During the Postmarketing Use of ZEMAIRA
| Number of Subjects Based on unique subjects. If a subject experienced more than one AR, the subject was only counted once. (Events per Subject-Year The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database. ) | Number of Infusions If there were multiple occurrences of ARs following a single infusion, only one occurrence was counted. (% of all Infusions) | |||
|---|---|---|---|---|
| ZEMAIRA (n=66, SY SY=subject-year. =28.72) | Prolastin (n=32), SY =3.83) | ZEMAIRA (n=1296) | Prolastin (n=160) | |
| ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate). | 54 (5.6) | 16 (3.8) | 160 (12.3) | 31 (19.4) |
| Serious ARs (Serious AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate). | 4 (0.2) | 1 (1.0) | 6 (0.5) | 1 (0.6) |
| ARs (AEs assessed by investigator as at least possibly related or occurring during or within 72 hours after the end of the infusion or for which causality assessment was missing or indeterminate). | Number of Subjects Based on unique subjects. If a subject experienced more than one AR of the same type, the subject was only counted once. (Events per Subject-Year The exposure adjusted event rate was based on total exposure time presented in subject-years and the total number of adverse reactions in the database. ) | Number of Infusions If more than one of the same type of an event occurred after an infusion, only one event was counted. (% of all Infusions) | ||
|---|---|---|---|---|
| ZEMAIRA (n=66, SY SY=subject-year. =28.72) | Prolastin (n=32, SY =3.83) | ZEMAIRA (n=1296) | Prolastin (n=160) | |
| Headache | 13 (0.7) | 5 (1.3) | 19 (1.5) | 5 (3.1) |
| Sinusitis | 10 (0.5) | 1 (0.3) | 13 (1.0) | 1 (0.6) |
| Upper Respiratory Infection | 10 (0.4) | 1 (0.3) | 10 (0.8) | 1 (0.6) |
| Bronchitis | 5 (0.2) | 0 (0.0) | 6 (0.5) | 0 (0.0) |
| Asthenia | 5 (0.2) | 2 (0.5) | 5 (0.4) | 2 (1.3) |
| Cough Increased | 5 (0.2) | 1 (0.5) | 5 (0.4) | 2 (1.3) |
| Fever | 4 (0.1) | 0 (0.0) | 4 (0.3) | 0 (0.0) |
| Injection Site Hemorrhage | 4 (0.1) | 0 (0.0) | 4 (0.3) | 0 (0.0) |
| Rhinitis | 4 (0.1) | 0 (0.0) | 4 (0.3) | 0 (0.0) |
| Sore Throat | 4 (0.1) | 0 (0.0) | 4 (0.3) | 0 (0.0) |
| Vasodilation | 4 (0.1) | 1 (0.3) | 4 (0.3) | 1 (0.6) |
| Serious COPD Exacerbations Episode = Serious exacerbations of COPD identified by investigators as meeting the Anthonisen criteria 1 plus Serious Adverse Event (SAE) terms COPD, Condition Aggravated, Bronchitis, Lower Respiratory Tract Infection, Pneumonia. Serious exacerbation events that overlap or occur within 1 day of one another were counted as single exacerbation episodes. | Episode | n | % | EAIR (95% CI) | Episode | n | % | EAIR 95% CI | Treatment Ratio for EAIR (95% CI) |
|---|---|---|---|---|---|---|---|---|---|
| N = total number of safety subjects, n = number of subjects within a category, % = (n/N)*100, CI = Confidence Interval. Subject time at risk: ZEMAIRA = 171.14 years, Placebo = 147.75 years, Early Start Group = 146.46 years, Delay Start Group = 124.71 years. EAIR = Exposure-Adjusted Incidence Rate (events/subject time at risk). The point estimates and confidence intervals for EAIR values were calculated using negative binomial models. | |||||||||
| RAPID Study (Years 1 – 2) | ZEMAIRA (N = 93) | Placebo (N = 87) | ZEMAIRA: Placebo | ||||||
| 25 | 15 | 16.1 | 0.15 (0.10-0.22) | 17 | 9 | 10.3 | 0.12 (0.07-0.18) | 1.26 (0.46 - 3.45) | |
| Extension Study (Years 3-4) | Early Start Early Start Group subjects were randomized to ZEMAIRA during the double-blind RAPID trial (years 1-2) and received open-label ZEMAIRA during the RAPID extension trial (years 3-4). (N = 76) | Delayed Start Delayed Start Group subjects were randomized to Placebo during the double-blind RAPID trial (years 1-2) and received open-label ZEMAIRA during the RAPID extension trial (years 3-4). (N = 64) | Early: Delayed | ||||||
| 37 | 19 | 25.0 | 0.25 (0.18 – 0.35) | 20 | 11 | 17.2 | 0.16 (0.10 – 0.25) | 1.58 (0.68 – 3.66) | |
| System Organ Class | Preferred Term/Symptoms |
|---|---|
| Blood and lymphatic system disorders | Lymph node pain |
| Gastrointestinal disorders | Nausea |
| General disorders and administration site conditions | Chills, infusion site reactions, facial, periorbital, lip and extremity swelling, chest pain |
| Nervous system disorders | Hypoesthesia, paresthesia, dizziness |
| Skin disorders | Hyperhidrosis, pruritus, rash including exfoliative and generalized, urticaria |
| Vascular disorders | Flushing |
Warnings & Cautions for Zemaira
Hypersensitivity to Other A 1 -PI Products
Observe any signs of hypersensitivity such as tachycardia, hypotension, confusion, syncope, oxygen consumption decrease, and pharyngeal edema when administering ZEMAIRA to patients with known hypersensitivity to an A 1 -PI product. If anaphylactic or severe anaphylactoid reactions occur, discontinue the infusion immediately. Have epinephrine and other appropriate supportive therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.
Hypersensitivity to IgA ZEMAIRA may contain trace amounts of IgA. Patients with selective or severe IgA deficiency can develop antibodies to IgA and, therefore, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. ZEMAIRA is contraindicated in IgA-deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
Transmissible Infectious Agents Because ZEMAIRA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current virus infections, and including virus inactivation/removal steps in the manufacturing process for ZEMAIRA. Despite these measures, ZEMAIRA, like other products made from human blood, may still potentially contain human pathogenic agents, including those not yet known or identified.
Thus, the risk of transmission of infectious agents cannot be totally eliminated. All infections thought by a physician to have been possibly transmitted by this product should be reported by the physician or other healthcare provider to the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Pregnancy Safety for Zemaira
Pregnancy Risk Summary No animal reproduction studies have been conducted with Zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. Since alpha 1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that Zemaira will cause harm to the fetus when given at recommended doses. However, Zemaira should be given with caution to pregnant women.
In the U.S. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Pediatric Use of Zemaira
Pediatric Use Safety and effectiveness in the pediatric population have not been established.
Contraindications for Zemaira
ZEMAIRA is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to ZEMAIRA or A 1 -PI protein. ZEMAIRA is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
Clinical Studies of Zemaira
Clinical trials were conducted pre-licensure with ZEMAIRA in 89 subjects (59 males and 30 females). The subjects ranged in age from 29 to 68 years (median age 49 years). Ninety-seven percent of the treated subjects had the PiZZ phenotype of A 1 -PI deficiency, and 3% had the M MALTON phenotype.
The objectives of the clinical trials were to demonstrate that ZEMAIRA augments and maintains serum levels of A 1 -PI above 11 µM (80 mg/dL) and increases A 1 -PI levels in ELF of the lower lung. In a double-blind, controlled clinical trial to evaluate the safety and efficacy of ZEMAIRA, 44 subjects were randomized to receive 60 mg/kg of either ZEMAIRA or Prolastin once weekly for 10 weeks. After 10 weeks, subjects in both groups received ZEMAIRA for an additional 14 weeks.
Subjects were followed for a total of 24 weeks to complete the safety evaluation. The mean trough serum A 1 -PI levels at steady state (Weeks 7-11) in the ZEMAIRA-treated subjects were statistically equivalent to those in the Prolastin-treated subjects within a range of ±3 µM. Both groups were maintained above 11 µM.
The difference between the ZEMAIRA and the Prolastin groups was not considered clinically significant and may be related to the higher specific activity of ZEMAIRA. In a subgroup of subjects enrolled in the trial (10 ZEMAIRA-treated subjects and 5 Prolastin-treated subjects), bronchoalveolar lavage was performed at baseline and at Week 11. A blinded retrospective analysis, which revised the prospectively established acceptance criteria showed that within each treatment group, ELF levels of antigenic A 1 -PI and A 1 -PI:NE complexes increased from baseline to Week 11 (Table 7).
Free elastase was immeasurably low in all samples. The post-treatment ANEC values in ELF were not significantly different between the ZEMAIRA-treated and Prolastin-treated subjects (mean 1725 nM vs. 1418 nM). No conclusions can be drawn about changes of ANEC values in ELF during the trial period as baseline values in the ZEMAIRA-treated subjects were unexpectedly high.
No A 1 -PI analytes showed any clinically significant differences between the ZEMAIRA and Prolastin treatment groups. Table 7. Change in ELF From Baseline to Week 11 in a Subgroup Analysis or any A 1 -PI product in influencing the course of pulmonary emphysema or pulmonary exacerbations has not been demonstrated in adequately powered, randomized, controlled clinical trials.
| Analyte | Treatment | Mean Change From Baseline | 90% CI |
|---|---|---|---|
| CI, confidence interval. | |||
| A 1 -PI (nM) | ZEMAIRA n=10 subjects. | 1358.3 | 822.6 to 1894.0 |
| Prolastin n=5 subjects. | 949.9 | 460.0 to 1439.7 | |
| ANEC (nM) | ZEMAIRA | -588.1 | -2032.3 to 856.1 |
| Prolastin | 497.5 | -392.3 to 1387.2 | |
| A 1 -PI:NE Complexes (nM) | ZEMAIRA | 118.0 | 39.9 to 196.1 |
| Prolastin | 287.1 | 49.8 to 524.5 | |
Drug information sourced from the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before making any medication decisions.
Ready to save on Zemaira?
Compare prescription prices at over 70,000 pharmacies and start saving today—no enrollment required.
Compare Zemaira Prices